RON-targeted antibody-drug conjugate therapy eliminates cancer stem-like cells and induces long-term tumor regressions in preclinical models of triple-negative breast cancer.

被引：0
|
作者：
Suthe, Sreedhar Reddy [1 ,2 ,3 ]
Yao, Hang-Ping [4 ]
Wang, Ming-Hai [1 ,2 ,3 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Canc Biol Res Ctr, Amarillo, TX USA
[2] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Biomed Sci, Amarillo, TX USA
[3] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX USA
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou, Zhejiang, Peoples R China
来源：
CANCER IMMUNOLOGY RESEARCH | 2020年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B54
引用
收藏
页码：108 / 108
页数：1
相关论文
共 26 条
  • [21] An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates
    Mungra, Neelakshi
    Nsole Biteghe, Fleury A.
    Huysamen, Allan M.
    Hardcastle, Natasha S.
    Bunjun, Rubina
    Naran, Krupa
    Lang, Dirk
    Richter, Wolfgang
    Hunter, Roger
    Barth, Stefan
    MOLECULAR PHARMACEUTICS, 2024, 21 (08) : 4098 - 4115
  • [22] Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models
    Yang, Mei
    Guan, Tian
    Chen, Chun-Fa
    He, Li-Fang
    Wu, Hao-Ming
    Zhang, Ren-Dong
    Li, Yun
    Lin, Yan-Chun
    Zeng, Haoyu
    Wu, Jun-Dong
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (08) : 285 - 294
  • [23] CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer
    Conley, Sarah J.
    Baker, Trenton L.
    Burnet, Joseph P.
    Thiesen, Rebecca L.
    Lazarus, Douglas
    Peters, Christian G.
    Clouthier, Shawn G.
    Eliasol, Scott
    Wicha, Max S.
    CANCER RESEARCH, 2015, 75
  • [24] Impacts of Tumor Stage at Diagnosis and Adjuvant Therapy on Long-Term Survival Outcomes in Patients With Triple-Negative Breast Cancer Achieving Pathologic Complete Response After Neoadjuvant Chemotherapy
    Chen, Ao-Xiang
    Chen, Xiao
    Li, Xin-Xin
    Guo, Zhang-Yin
    Cao, Xu-Chen
    Wang, Xin
    Zhang, Bin
    CLINICAL BREAST CANCER, 2025, 25 (01) : e30 - e39
  • [25] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [26] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer Robinson
    Starodub, Alexander
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Ocean, Allyson J.
    Berlin, Jordan
    Messersmith, Wells A.
    Thomas, Sajeve Samuel
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Goldenberg, David M.
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
123